HealthQuill Novo Nordisk
Overdose of weight-loss drugs and dosing errors by patients and healthcare providers have led to adverse events, including hospitalisation, the USFDA warned.
Drugs Health Pharma

FDA issues warning over weight-loss drug overdose, dosing errors

Overdose of weight-loss drugs and dosing errors by patients and healthcare providers have led to adverse events, including hospitalisation, the USFDA warned.

Read More
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic adults with obesity, according to a statement from the EU regulator.
Drugs Health Pharma

Wegovy gets EU regulator backing on lowering heart risks in obese people

The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.

Read More
The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering from heart problems or stroke.
Drugs Health Pharma

Novo Nordisk’s Wegovy gets UK regulator nod to treat heart risks

The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering.

Read More
Novo Nordisk, has been denied approval for its type 1 diabetic medicine by the USFDA, according to the Danish drugmaker.
Drugs Health Pharma

FDA declines approval for Novo Nordisk’s diabetic medicine

Novo Nordisk, has been denied approval for its type 1 diabetic medicine by the USFDA, according to the Danish drugmaker.

Read More
June 27, 2024: Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss of 5.7 Danish crowns or $817 million in the second quarter of this year.
Drugs Health Pharma

Novo’s end-stage hypertension trial drug fails, $817m impairment loss

Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss.

Read More
Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.
Drugs Health Pharma

Teva to sell generic version of Novo Nordisk’s diabetic drug in US

Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.

Read More
Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic disease drugs, according to a company statement.
Drugs Health Pharma

Novo Nordisk to set up $4.1 billion injectables facility in US’s North Carolina

Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic.

Read More
The World Health Organization has issued a medical product alert on falsified semaglutides, an active ingredient in Ozempic, a diabetic drug made by Novo Nordisk and weight-loss medication Wegovy.
Drugs Health Pharma

WHO issues medical alert on falsified weight-loss, diabetic drugs

The World Health Organization has issued a medical product alert on falsified semaglutides, an active ingredient in Ozempic, a diabetic drug made by.

Read More
The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people with type 1 diabetes, with seven members voting for and four against.
Drugs Health Pharma

FDA panel rejects Novo Nordisk’s weekly jab to treat type 1 diabetes

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people.

Read More
Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular weight-loss drug Wegovy, as it announced its January to March operating profit rose 27% to Danish kroner 31.8 billion.
Drugs Health Pharma

Novo Nordisk raises sales forecast on strong demand for anti-obesity drug

HQ Team May 2, 2024: Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular.

Read More
X